Multimodal microglial and kynurenine pathway alterations across the affective-psychosis spectrum: a systematic review of patterns, heterogeneity, and dimensional implications.

Mol PsychiatryApr 21, 2026 (epub)
Clinical ResearchPsychiatryOpen access

Madeleine Nussbaumer, Paul C Guest, Kolja Schiltz et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examined immune dysregulation in major depressive disorder (MDD), bipolar disorder (BD), and schizophrenia (SCZ) through microglial and kynurenine pathway alterations. MDD exhibited the most consistent in vivo signals with increased TSPO binding in frontolimbic regions, showing lower heterogeneity compared to SCZ. The findings suggest that microglial changes are better understood through biological subgroups rather than categorical diagnoses.

Key findings

  • MDD showed increased TSPO binding in frontolimbic regions, indicating immune dysregulation.
  • SCZ exhibited heterogeneous TSPO-PET findings with small decreases or no change.
  • Postmortem studies indicated either activation-marker increases or loss of homeostatic microglial signatures in SCZ.
  • BD evidence was limited, with only one TSPO-PET study reporting hippocampal increases.

Why it matters

Understanding the immune mechanisms underlying affective and psychotic disorders can inform future research and therapeutic strategies. This review highlights the importance of considering biological subgroups and symptom dimensions in psychiatric research.

What to keep in mind

The review notes limited cellular specificity of TSPO-PET, small sample sizes, and a focus on few cortical/limbic regions in postmortem studies.

Source

Published in Mol Psychiatry. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.